The use of fulvestrant, a parenteral endocrine agent, in intestinal obstruction due to metastatic lobular breast carcinoma.
BACKGROUND
The role of fulvestrant in the management of intestinal obstruction associated with lobular carcinoma has not been specifically described.


METHODS
Herein we present two cases where fulvestrant, as the only available parenteral endocrine agent for postmenopausal advanced breast cancer has the opportunity to provide a means to initiate treatment in those patients who present with varying degrees of intestinal obstruction.


CONCLUSIONS
Fulvestrant may obviate the use of chemotherapy while achieving sustained clinical benefit with less toxicity, in appropriately selected patients.
Tang
Jasmine Y M
JY
Division of Breast Surgery, University of Nottingham, Nottingham, UK. jaytea@gmail.com
Rampaul
Rajendra Singh
RS
Cheung
Kwok L
KL
D000368:Aged; D000369:Aged, 80 and over; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D018275:Carcinoma, Lobular / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D004958:Estradiol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D000077267:Fulvestrant; D006801:Humans; D007415:Intestinal Obstruction / Q000209:etiology*; D008875:Middle Aged; D009362:Neoplasm Metastasis
D018931:Antineoplastic Agents, Hormonal; D000077267:Fulvestrant; D004958:Estradiol